Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Jang Hee | - |
dc.contributor.author | Lee, Seung Hwan | - |
dc.contributor.author | Ham, Won Sik | - |
dc.contributor.author | Han, Woong Kyu | - |
dc.contributor.author | Rha, Koon Ho | - |
dc.contributor.author | Choi, Young Deuk | - |
dc.contributor.author | Hong, Sung Joon | - |
dc.contributor.author | Yoon, Young Eun | - |
dc.date.accessioned | 2022-07-13T05:53:56Z | - |
dc.date.available | 2022-07-13T05:53:56Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/151522 | - |
dc.description.abstract | Background: To assess the prognostic and predictive factors of time to treatment failure (TTF) and overall survival (OS), respectively, in patients with metachronous metastatic renal cell carcinoma (mRCC) who were treated with targeted agents. Materials and Methods: We retrospectively reviewed metachronous mRCC patients, defined as individuals diagnosed with metastatic disease > 3 months after initial nephrectomy, treated at an institute since 2005. Cox proportional hazard regression analysis was performed to discover the most determinant variables associated with TTF and OS. Results: Sarcomatoid features, absence of metastasectomy, multiple site metastasis, time to metastasis < 1.5 year, and increased corrected calcium were independent prognostic factors of OS. The low risk group (0-1 risk factors) did not reach the median OS, whereas the OS for the intermediate (2 risk factors) and high risk groups (3-5 risk factors) were 58.6 and 23.6 months, respectively (p < 0.001). When a death event was considered the dependent factor, the area under the receiver operating characteristic curve was significantly higher than in the existing International mRCC Database Consortium (IMDC; p= 0.010) and Memorial Sloan Kettering Cancer Center (MSKCC; p= 0.010) risk criteria models. Conclusion: Initial tumor size or T stage did not affect TTF or OS. Patients who could not undergo metastasectomy and rapidly developed multiple metastases with higher corrected calcium and initial tumors with sarcomatoid features were less likely to benefit from targeted therapy; thus, the new agents under development or clinical trials could be more helpful than the use of standard targeted agents. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.title | Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Young Eun | - |
dc.identifier.doi | 10.18632/oncotarget.20230 | - |
dc.identifier.scopusid | 2-s2.0-85030458939 | - |
dc.identifier.wosid | 000412111300052 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.8, no.45, pp.78825 - 78837 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 8 | - |
dc.citation.number | 45 | - |
dc.citation.startPage | 78825 | - |
dc.citation.endPage | 78837 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | SUNITINIB | - |
dc.subject.keywordPlus | NEPHRECTOMY | - |
dc.subject.keywordPlus | EVEROLIMUS | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | PREDICTOR | - |
dc.subject.keywordPlus | PAZOPANIB | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | renal cell carcinoma | - |
dc.subject.keywordAuthor | targeted therapy | - |
dc.subject.keywordAuthor | metastasis | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | survival | - |
dc.identifier.url | https://www.oncotarget.com/article/20230/text/ | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.